Prodrugs comprising an insulin linker conjugate

Patent metadata

Field	Value
Publication number	US-9457066-B2
Application number	US-201514712369-A
Country	US
Kind code	B2
Filing date	May 14, 2015
Priority date	Jul 31, 2009
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I),

wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.

First claim

The invention claimed is:

1. A prodrug comprising:
a hydrogel (Z) with backbone moieties of formula C-(A-Hyp) 4 , wherein:
each A is independently selected from the formula —(CH 2 ) n1 (OCH 2 CH 2 ) n X′—, wherein:
n1 is 1 or 2;
n is an integer ranging from 5 to 50; and
X′ is an amide linkage linking A and Hyp;

each Hyp is independently selected from hyperbranched polypeptides comprising lysine;
the backbone moieties are crosslinked by poly(ethylene glycol)-based crosslinker moieties, comprising m ethylene glycol units, wherein m is an integer ranging from 10-70, and terminated by at least two hydrolytically degradable bonds;

a linker L 2 connected to the backbone moiety, wherein:
L 2 is a single chemical bond or is a C 1-20 alkyl chain, which is optionally interrupted by one or more groups independently selected from —O— and C(O)N(R 3aa ), and further optionally substituted with one or more groups independently selected from OH and C(O)N(R 3aa R 3aaa ), wherein R 3aa and R 3aaa are independently selected from the group consisting of H and C 1-4 alkyl; and
L 2 is attached to Z via a terminal group selected from the group consisting of

 wherein L 2 is attached to the sulfur atom in structure X and Z is attached to the nitrogen atom in structure X, or L 2 is attached to the nitrogen atom in structure XI and Z is attached to the sulfur atom in structure XI; and

an insulin-linker conjugate D-L 1 , wherein:
D is an insulin; and
L 1 is:

 wherein:
the dashed line indicates the point of attachment of L 1 to one of the amino groups of insulin through an amide bond;
X is N(R 3 );
R 1a is selected from the group consisting of H, NH(R 2b ), N(R 2b )C(O)R 4 , and C 1-4 alkyl;
R 1 , R 2 , R 2a , R 2b , R 3 , and R 4 are independently selected from the group consisting of H and C 1-4 alkyl, and optionally substituted with L 2 -Z; and
L 1 is substituted with one L 2 -Z provided that the hydrogen marked with the asterisk in formula (I) is not replaced;

or a pharmaceutically acceptable salt thereof, wherein said prodrug is in the form of microparticles.

2. The prodrug of claim 1 , wherein in formula (I) R 2 is replaced by L 2 -Z.

3. The prodrug of claim 1 , wherein in formula (I) R 1 is replaced by L 2 -Z.

4. The prodrug of claim 1 , wherein the insulin is attached to L 1 through nitrogen N αA1 .

5. The prodrug of claim 1 , wherein the insulin is a recombinant human insulin.

6. The prodrug of claim 5 , wherein the recombinant human insulin is attached to L 1 through the nitrogen of a lysine side chain of the insulin.

7. The prodrug of claim 1 , wherein the backbone moieties have a molecular weight in the range of from 1 kDa to 20 kDa.

8. The prodrug of claim 1 , wherein the crosslinker moieties have a molecular weight in the range of from 0.5 kDa to 5 kDa.

9. The prodrug of claim 1 , wherein the prodrug has the structure of formula (IIb);

10. The prodrug of claim 1 , wherein the backbone moieties comprise a branching core of the following formula:

wherein the dashed line indicates attachment to the remainder of the backbone moieties.

11. The prodrug of claim h wherein the backbone moieties comprise a structure of the following formula:

wherein n is an integer of from 5 to 50 and the dashed line indicates attachment to the rest of the molecule.

12. The prodrug of claim 1 , wherein the backbone moieties comprise a hyperbranched moiety Hyp of the following formula:

wherein the dashed lines indicate attachment to the rest of the molecule and carbon atoms marked with asterisks indicate S-configuration.

13. The prodrug of claim 1 , wherein the backbone moieties are attached to at least one spacer of the following formula:

wherein one of the dashed lines indicates attachment to the hyperbranched moiety Hyp and the second dashed line indicates attachment to the rest of the molecule; and wherein m is an integer of from 2 to 4.

14. The prodrug of claim 1 , wherein the backbone moieties are attached to at least one spacer of the following formula:

wherein the dashed line marked with the asterisk indicates the bond between the hydrogel and the nitrogen atom in structure X,
wherein the other dashed line indicates attachment to Hyp, and wherein p is an integer of from 0 to 10.

15. The prodrug of claim 1 , wherein the backbone moieties are linked together through crosslinker moieties comprising the following structure:

wherein q is an integer from 3 to 100.

16. The prodrug of claim 1 , wherein the microparticles have a diameter of between 20 and 100 micrometer.

17. A pharmaceutical composition comprising the prodrug of claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient.

18. The pharmaceutical composition according to claim 17 , wherein the pharmaceutical composition is a multi-dose pharmaceutical composition.

19. The pharmaceutical composition according to claim 17 , further comprising one or more additional biologically active agents.

20. A dry pharmaceutical composition according to claim 17 .

21. A lyophilized pharmaceutical composition according to claim 20 .

22. A single dose pharmaceutical composition according to claim 17 .

23. A suspension comprising the pharmaceutical composition according to claim 17 .

24. A method of treating a disease or disorder selected from the group consisting of hyperglycemia, pre-diabetes, impaired glucose tolerance, diabetes type I, and diabetes type II comprising administering to a patient in need thereof the prodrug of claim 1 , thereby treating the disease or disorder.

Assignees

• Sanofi Aventis Deutschland

Inventors

• Rau Harald
• Cleemann Felix
• Hersel Ulrich
• Kaden-Vagt Silvia
• Lessmann Torben
• Wegge Thomas

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• C07K14/62 Primary

  Insulins · CPC title

• Y10T428/13

  Hollow or container type article [e.g., tube, vase, etc.] · CPC title